Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.71 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 11/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744648 | 0.83 | MKNK1 (1.00) | MKNK1KLK7DYRK1AFYN | |
| SCHEMBL22189861 | 0.81 | MKNK1 (0.77) | MKNK1KLK7DYRK1ADYRK3CCNA2 | |
| SCHEMBL1054031 | 0.77 | MKNK1 (0.71) | MKNK1KLK7DYRK1APRMT5WDR77 | |
| SCHEMBL16331591 | 0.77 | MKNK1 (0.71) | MKNK1KLK7DYRK1ADYRK3CCNA2 | |
| SCHEMBL3359311 | 0.74 | FYN (0.47) | MKNK1DYRK1ADYRK3CCNA2CDK2 | |
| SCHEMBL31403778 | 0.74 | MKNK1 (0.62) | MKNK1KLK7DYRK1APRMT5WDR77 | |
| SCHEMBL22322759 | 0.73 | MKNK1 (0.41) | MKNK1LRRK2 | |
| SCHEMBL16332731 | 0.73 | MKNK1 (0.60) | MKNK1KLK7DYRK1ADYRK3CCNA2 | |
| SCHEMBL16331301 | 0.73 | MKNK1 (0.60) | MKNK1KLK7DYRK1ADYRK3CCNA2 | |
| SCHEMBL16332724 | 0.73 | MKNK1 (0.65) | MKNK1KLK7DYRK1ADYRK3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| EP-2178879-B1 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
| EP-2178879-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009037394-A2 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | TLR7, IFNAR1, CBR3 | MKNK1 4608/4885KLK7 2592/4885DYRK1A 2639/4885 |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | IFNAR1, TLR7, CBR3 | MKNK1 4579/4885KLK7 2590/4885DYRK1A 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.